Dalotuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Dalotuzumab
Accession Number
DB11840
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • MK-0646
Categories
UNII
6YI1L648RH
CAS number
1005389-60-5

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Dalotuzumab.
AbituzumabThe risk or severity of adverse effects can be increased when Dalotuzumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Dalotuzumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Dalotuzumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Dalotuzumab.
AducanumabThe risk or severity of adverse effects can be increased when Dalotuzumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Dalotuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dalotuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Dalotuzumab.
AmatuximabThe risk or severity of adverse effects can be increased when Dalotuzumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911246
Wikipedia
Dalotuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentBreast Cancer2
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentMultiple Myeloma (MM) / Tumors, Solid1
1CompletedTreatmentNeoplasms2
1CompletedTreatmentTumors, Solid1
1TerminatedTreatmentNeoplasms Malignant1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
1, 2CompletedTreatmentLung Cancers1
1, 2TerminatedTreatmentBreast Cancer1
2CompletedTreatmentBreast Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2CompletedTreatmentMetastatic Colorectal Cancers1
2CompletedTreatmentMetastatic Neuroendocrine Tumors / Neuroendocrine Tumors1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentRectal Neoplasms1
2WithdrawnTreatmentLung Cancers1
2WithdrawnTreatmentMetastatic Colorectal Cancers1
Not AvailableNot Yet RecruitingNot AvailableOvarian Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:52 / Updated on November 02, 2019 02:50